Export 17 results:
Author Title Type [ Year(Desc)]
Filters: Author is Anderson, Evan J  [Clear All Filters]
2017
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
2019
K. L. Kotloff, Shirley, D. - A. T., C Creech, B., Frey, S. E., Harrison, C. J., Staat, M., Anderson, E. J., Dulkerian, S., Thomsen, I. P., Al-Hosni, M., Pahud, B. A., Bernstein, D. I., Yi, J., Petrikin, J. E., Haberman, B., Stephens, K., Stephens, I., Oler, R. E., and Conrad, T. M., “Mupirocin for Decolonization of Infants in Neonatal Intensive Care Units.”, Pediatrics, vol. 143, no. 1, 2019.
N. G. Rouphael, Hurwitz, S. J., Hart, M., Beck, A., Anderson, E. J., Deye, G., Osborn, B., Cai, S. Yi, Focht, C., Amegashie, C., Bowlin, T. L., Brooks, J., and Mulligan, M. J., “Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers.”, Antimicrob Agents Chemother, vol. 63, no. 9, 2019.
F. M. Munoz, Anderson, E. J., Bernstein, D. I., Harrison, C. J., Pahud, B., Anderson, E., C Creech, B., Berry, A. A., Kotloff, K. L., Walter, E. B., Atmar, R. L., Bellamy, A. R., Chang, S., and Keitel, W. A., “Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.”, Vaccine, vol. 37, no. 36, pp. 5161-5170, 2019.
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
2020
K. M. Maner-Smith, Goll, J. B., Khadka, M., Jensen, T. L., Colucci, J. K., Gelber, C. E., Albert, C. J., Bosinger, S. E., Franke, J. D., Natrajan, M., Rouphael, N., Johnson, R. A., Sanz, P., Anderson, E. J., Hoft, D. F., Mulligan, M. J., Ford, D. A., and Ortlund, E. A., “Alterations in the Human Plasma Lipidome in Response to Tularemia Vaccination.”, Vaccines (Basel), vol. 8, no. 3, 2020.
L. Lai, Rouphael, N., Xu, Y., Sherman, A. C., Edupuganti, S., Anderson, E. J., Lankford-Turner, P., Wang, D., Keitel, W., McNeal, M. M., Cross, K., Hill, H., Bellamy, A. R., and Mulligan, M. J., “Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
L. Lai, Ault, K., Rouphael, N., Beck, A., Domjahn, B., Xu, Y., Anderson, E. J., Cheng, A., Nakamura, A., Hoagland, R. J., Kelley, C., Edupuganti, S., Mask, K., Nesin, M., Unger, E. R., Panicker, G., David, H., and Mulligan, M. J., “Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure.”, Vaccines (Basel), vol. 8, no. 3, 2020.
E. J. Anderson, Lopman, B., Yi, J., Libster, R., C Creech, B., El-Khorazaty, J., Baqar, S., Yildirim, I., Kao, C., Rouphael, N., Shane, A. L., and Edwards, K., “Effect of Concomitant Antibiotic and Vaccine Administration on Serologic Responses to Rotavirus Vaccine.”, J Pediatric Infect Dis Soc, vol. 9, no. 4, pp. 479-482, 2020.
L. A. Jackson, Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., Padilla, M., Mascola, J. R., Neuzil, K. M., Bennett, H., Sun, W., Peters, E., Makowski, M., Albert, J., Cross, K., Buchanan, W., Pikaart-Tautges, R., Ledgerwood, J. E., Graham, B. S., and Beigel, J. H., “An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.”, N Engl J Med, 2020.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., “Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
E. J. Anderson, Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A. B., Flach, B., Lin, B. C., Doria-Rose, N. A., O'Dell, S., Schmidt, S. D., Corbett, K. S., Swanson, P. A., Padilla, M., Neuzil, K. M., Bennett, H., Leav, B., Makowski, M., Albert, J., Cross, K., Edara, V. Viswanadh, Floyd, K., Suthar, M. S., Martinez, D. R., Baric, R., Buchanan, W., Luke, C. J., Phadke, V. K., Rostad, C. A., Ledgerwood, J. E., Graham, B. S., and Beigel, J. H., “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.”, N Engl J Med, 2020.
J. B. Goll, Li, S., Edwards, J. L., Bosinger, S. E., Jensen, T. L., Wang, Y., Hooper, W. F., Gelber, C. E., Sanders, K. L., Anderson, E. J., Rouphael, N., Natrajan, M. S., Johnson, R. A., Sanz, P., Hoft, D., and Mulligan, M. J., “Transcriptomic and Metabolic Responses to a Live-Attenuated Vaccine.”, Vaccines (Basel), vol. 8, no. 3, 2020.
2021
A. Pegu, O'Connell, S. E., Schmidt, S. D., O'Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., Flach, B., Jackson, L., Leav, B., Ledgerwood, J. E., Luke, C. J., Makowski, M., Nason, M. C., Roberts, P. C., Roederer, M., Rebolledo, P. A., Rostad, C. A., Rouphael, N. G., Shi, W., Wang, L., Widge, A. T., Yang, E. Sung, Beigel, J. H., Graham, B. S., Mascola, J. R., Suthar, M. S., McDermott, A. B., Doria-Rose, N. A., Arega, J., Beigel, J. H., Buchanan, W., Elsafy, M., Hoang, B., Lampley, R., Kolhekar, A., Koo, H., Luke, C., Makhene, M., Nayak, S., Pikaart-Tautges, R., Roberts, P. C., Russell, J., Sindall, E., Albert, J., Kunwar, P., Makowski, M., Anderson, E. J., Bechnak, A., Bower, M., Camacho-Gonzalez, A. F., Collins, M., Drobeniuc, A., Edara, V. Viswanadh, Edupuganti, S., Floyd, K., Gibson, T., Ackerley, C. M. Grimsley, Johnson, B., Kamidani, S., Kao, C., Kelley, C., Lai, L., Macenczak, H., McCullough, M. Paine, Peters, E., Phadke, V. K., Rebolledo, P. A., Rostad, C. A., Rouphael, N., Scherer, E., Sherman, A., Stephens, K., Suthar, M. S., Teherani, M., Traenkner, J., Winston, J., Yildirim, I., Barr, L., Benoit, J., Carste, B., Choe, J., Dunstan, M., Erolin, R., Ffitch, J., Fields, C., Jackson, L. A., Kiniry, E., Lasicka, S., Lee, S., Nguyen, M., Pimienta, S., Suyehira, J., Witte, M., Bennett, H., Altaras, N. Emil, Carfi, A., Hurley, M., Leav, B., Pajon, R., Sun, W., Zaks, T., Coler, R. N., Larsen, S. E., Neuzil, K. M., Lindesmith, L. C., Martinez, D. R., Munt, J., Mallory, M., Edwards, C., Baric, R. S., Berkowitz, N. M., Boritz, E. A., Carlton, K., Corbett, K. S., Costner, P., Creanga, A., Doria-Rose, N. A., Douek, D. C., Flach, B., Gaudinski, M., Gordon, I., Graham, B. S., Holman, L. S., Ledgerwood, J. E., Leung, K., Lin, B. C., Louder, M. K., Mascola, J. R., McDermott, A. B., Morabito, K. M., Novik, L., O'Connell, S., O'Dell, S., Padilla, M., Pegu, A., Schmidt, S. D., Shi, W., Swanson, P. A., Talana, C. A., Wang, L., Widge, A. T., Yang, E. Sung, Zhang, Y., Chappell, J. D., Denison, M. R., Hughes, T., Lu, X., Pruijssers, A. J., Stevens, L. J., Posavad, C. M., Gale, M., Menachery, V., and Shi, P. - Y., “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
P. Winokur, Sahly, H. M. El, Mulligan, M. J., Frey, S. E., Rupp, R., Anderson, E. J., Edwards, K. M., Bernstein, D. I., Schmader, K., Jackson, L. A., Chen, W. H., Hill, H., and Bellamy, A., “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
2022
N. Rouphael, Beck, A., Kirby, A. E., Liu, P., Natrajan, M. S., Lai, L., Phadke, V., Winston, J., Raabe, V., Collins, M. H., Girmay, T., Alvarez, A., Beydoun, N., Karmali, V., Altieri-Rivera, J., Lindesmith, L. C., Anderson, E. J., Wang, Y., El-Khorazaty, J., Petrie, C., Baric, R. S., Baqar, S., Moe, C. L., and Mulligan, M. J., “Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum”, J Infect Dis, vol. 226, no. 10, pp. 1771-1780, 2022.
L. Lai, Rouphael, N., Xu, Y., Kabbani, S., Beck, A., Sherman, A., Anderson, E. J., Bellamy, A., Weiss, J., Cross, K., and Mulligan, M. J., “An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT) cells and antibody responses.”, Vaccine, vol. 40, no. 49, pp. 7065-7072, 2022.